

INCIDENCE OF CYTOMEGALOVIRUS DISEASE IN KIDNEY TRANSPLANT RECIPIENTS RECEIVING EVEROLIMUS AND REDUCED TACROLIMUS DOSES: A COHORT RETROSPECTIVE ANALYSIS

Incidência de Doença por Citomegalovirus em receptores de transplante renal recebendo Everolimus e dose reduzida de Tacrolimus: Análise de uma coorte retrospectiva

Juliana Bastos, Vinícius Sardão Colares, Alexandre Arantes Pires, Camila Marinho Assunção, Glaucio Souza, Marcio de Sousa, Gustavo Fernandes Ferreira

RESUMO

Introduction: Cytomegalovirus (CMV) is the most common viral pathogen occurring in postrenal transplantation. CMV infection usually develops during the first few months after transplantation. The success of CMV prophylaxis with antivirals has resulted in a decrease in the incidence of CMV infection. However, CMV remains a significant pathogen, associated with allograft rejection and loss, mortality, interstitial fibrosis and tubular atrophy (IF/TA) in protocol biopsies, and increased post-transplant costs. **Purpose:** To determine the incidence of cytomegalovirus disease in kidney transplant recipients receiving Everolimus and reduced Tacrolimus doses. **Material and Methods:** All low immunological risk patients, >18 years old whom received kidney transplantation at Santa Casa de Misericórdia de Juiz de Fora between January 2013 and February 2017 were retrospectively assessed. The first group received induction therapy with Basiliximab, and the post-operative maintenance regimen included Tacrolimus, Mycophenolic acid and Prednisone (BAS/MPS), and the second group received Polyclonal antilymphocyte globulins (2,25mg/kg) as induction therapy, and then low dose of Tacrolimus (2mg/10kg/day), Everolimus and Prednisone as maintenance regimen (r-ATG/EVR). None of the patients received pharmacological prophylaxis or preemptive therapy against CMV. **Results:** Patients receiving EVR showed a lower incidence of CMV when compared to those receiving MPS (4.2% x 17.5%, $p=0.005$). There was an important difference in the time of hospitalization to treat CMV disease. Patients of the MPS stayed hospitalized for about 20 days more than the EVR group ($p=0.005$). There was no difference as to the incidence of rejection, delayed graft function or graft survival. **Conclusion:** Results from this trial conducted in low immunological risk kidney transplant recipients receiving no CMV prophylaxis demonstrated that EVR was associated to a decrease in CMV disease incidence when compared to MPS. These data suggest that kidney transplant recipients receiving EVR may not need CMV prophylaxis.

Keywords: Cytomegalovirus; Kidney Transplant; mTOR inhibitors

Instituição:

Departamento de Transplantes da Santa Casa de Misericórdia de Juiz de Fora - Juiz de Fora/MG

Correspondência:

Gustavo Fernandes Ferreira
E-mail: gustavofferreira@gmail.com

Recebido em: 24/06/2021

Aceito em: 19/07/2021

INTRODUCTION

Cytomegalovirus (CMV) is the most common viral pathogen occurring in postrenal transplantation.¹⁻⁴ CMV infection usually develops along the first few post-transplantation months. The clinical picture of infection ranges from self-limiting asymptomatic viremia to CMV infection (fever, malaise, leukopenia), to life-threatening tissue-invasive disease (i.e., pneumonia, hepatitis, multiorgan failure).^{5,6} The success of CMV prophylaxis with antivirals has resulted in a decrease in the incidence

of CMV infection^{1, 7-10} However, CMV remains a significant pathogen, associated with allograft rejection and loss, mortality, interstitial fibrosis and tubular atrophy (IF/TA) in protocol biopsies, and increased the post-transplant costs^{1, 11-15}

The prevalence of CMV seropositivity varies around the world, ranging from 40% to 100%, with lower rates in Europe, North America, and Australia and with higher rates in Africa and Asia.^{5,16} Recipients who are seronegative for CMV are at the greatest risk of disease after receiving allografts from infected, seropositive donors (donor positive/recipient negative combinations).^{6,17} Without adequate preventive therapy to control viral replication, it is estimated that approximately 58% to 80% of solid organ transplant recipients develop active CMV disease.¹⁷⁻¹⁹

Universal prophylaxis and preemptive therapy have been used to manage CMV infection, but both are associated to disadvantages.²⁰⁻²³ Pre-emptive therapy does not prevent viral replication, an event that has been associated to poorer transplant outcomes, and requires intensive logistical coordination.^{20,21,23-26} Universal prophylaxis is not fully effective, and its duration of 3–6 months varies according to the perceived risk is associated to bone marrow adverse events, possibly leading to drug dose discontinuation.^{20,27,28} and it is associated to a significant incidence of late CMV infection and drug resistance.^{20,22,29,30} Ganciclovir and valganciclovir have become the antiviral agents of choice for prevention and treatment of CMV infection in these patients.^{27,28,31} However, with the widespread use of these drugs, an increase in the incidence of ganciclovir-resistant (GanR) CMV strains has been reported.³¹ Among SOT recipients, GanR CMV infection may be associated with aggressive clinical courses, organ dysfunction, and mortality.^{31,32} Moreover, GanR CMV poses particular management difficulties because foscarnet and cidofovir can be extremely toxic.^{31,32} An effective immunosuppressive drug in preventing rejection that attenuated the incidence of CMV events would be beneficial to patients.¹

In recent years, many observational studies showed that mammalian target of rapamycin inhibitors (mTORi) has a protective effect for CMV infection after solid organ transplantation, especially after KT.^{1, 5,17,33-40} CMV replication is dependent upon 1 of 2 mTOR pathways, and in vitro studies support an association between mTOR inhibitors and decreased CMV.^{1,41} The risk to acquire CMV on an mTOR-I was lower than half when compared to patients on CNI. Corresponding to the “natural” peak of CMV infections after transplantation, the anti-CMV effect seemed most pronounced in the

studies using de novo mTOR-Is or very early conversion approaches.⁵ Moreover, there is also some evidence on the efficacy of the conversion from calcineurin inhibitors (CNI) to mTORi to control the replication of ganciclovir-resistant CMV.^{31,33,42}

MATERIALS AND METHODS

Population

This single-center retrospective cohort analysis aimed to assess the impact of the use of mTORi on the risk for CMV disease in low immunological risk patients of de novo kidney transplant receiving no pharmacological prophylaxis.

All low immunological risk patients, >18 years old whom received kidney transplantation at Santa Casa de Misericórdia de Juiz de Fora between January 2013 and February 2017 were retrospectively assessed. Patients were followed till 01/01/2018 or until they completed 1 post-transplantation year.

Patients were categorized according to the immunosuppression regimen, regardless the need for treatment discontinuation (intention-to-treat analysis).


Immunosuppression protocol

In 2013, all patients received induction therapy with Basiliximab, and the post-operative maintenance regimen included Tacrolimus, Mycophenolic acid and Prednisone (BAS/MPS). From January 2015 all patients received Polyclonal antilymphocyte globulins (2,25mg/kg) as induction therapy and then low dose of Tacrolimus (2mg/10kg/day), Everolimus and Prednisone as maintenance regimen (r-ATG/EVR). In 2014 there was a transition between the protocols when only recipients of living kidney donation were allocated in the r-ATG/EVE group. None of the patients received pharmacological prophylaxis or preemptive therapy against CMV.

Exclusion criteria included patients who lost graft within the first week of transplantation (Figure 1).

Definitions

We considered low immunological risk patients with panel reactive antibody (PRA) lower than 50% and without donor-specific antibodies (DSA). The diagnosis of CMV disease was made from the clinical suspicion, next confirmed by quantitative plasma PCR >1.000 copies/ml. Delayed graft function (DGF) was defined as the need for dialysis during the first week after transplantation. Biopsy confirmed acute rejection episodes were classified according to Banff's 2009 classification.²⁸

Figure 1 - Exclusion criteria

CMV disease was defined as positive PCR and symptoms (fever; malaise or fatigue; leukopenia or neutropenia; atypical lymphocytosis; thrombocytopenia) or tissue-invasive disease.

This study was approved by the Santa Casa de Misericórdia de Juiz de Fora ethical committee on 04/11/2017 (Parecer Consubstanciado no. 2.011.836). The informed consent was exempted.

RESULTS

There were no significant differences between demographic characteristics of the recipients, except

for the panel reactive antibodies class II, which was lower in the EVR group (**Table 1**). When analyzing the donor characteristics, we observed that the number of mismatches was higher in the MPS group; there were more living and male donors in the EVR group, and the cold ischemia type was higher in this group, as well. There was a significant difference in the combination of donor and recipient CMV IgG pre-transplantation serologic status, and therefore we analyzed separately the incidence of CMV disease in both positive and negative recipients.

Patients receiving EVR showed a lower incidence of CMV disease when compared to those receiving MPS (4.2% x 17.5%, $p=0.005$, **Figure 2, Table 2**).


Figure 2 - CMV disease cumulative incidence

Table 1 - Demographic characteristics

Variable	r-ATG/EVR (N = 96)	BAS/MPS (N = 97)	P
Recipient age (mean ± SD)	46.2 ± 12.4	49.3 ± 12.5	0.087
Recipient gender, male, N (%)	64 (66.7)	71 (73.2)	0.323
Body mass index (Kg/m ²), (mean ± SD)	25.0 ± 4.3	24.9 ± 4.2	0.886
Cause of chronic kidney disease, N (%)			0.146
Undetermined	36 (37.5)	28 (28.9)	
Hypertension	17 (17.7)	31 (32)	
Diabetes mellitus	14 (14.6)	(15.5)	
Polycystic disease	9 (9.4)	5 (5.2)	
Glomerulonephritis	9 (9.4)	11 (11.3)	
Urological disease	3 (3.1)	0	
Other	8 (8.3)	7 (7.2)	
Time on dialysis, months (mean ± SD)	35.1 ± 36.9	37.3 ± 40.2	0.330
Type of treatment, N (%)			0.42
Hemodialysis	89 (92.7)	93 (95.9)	
Peritoneal dialysis	4 (4.2)	3 (3.1)	
Preemptive transplantation	3 (3.1)	1 (1)	
Panel reactive antibodies, (%)			
Class I (mean ± SD)	4.0 ± 10.9	2.7 ± 5.6	0.088
Class II (mean ± SD)	0.4 ± 3.3	3.6 ± 11.1	0.002
HLA mismatches (mean ± SD)	3.7 ± 1.3	4.3 ± 1.3	0.001
CMV IgG serologic status, N (%)			0.000
Donor (+)/Recipient (+)	70 (72.9)	42 (43.3)	
Donor (+)/Recipient (-)	1 (1)	4 (4.1)	
Donor (-)/Recipient (+)	17 (17.7)	15 (15.5)	
Donor (-)/Recipient (-)	1 (1)	1 (1)	
Donor (unk)/Recipient (-)	0	2 (2,1)	
Donor (unk)/Recipient (+)	7 (7.3)	33 (34)	
Retransplantation	0	0	
Donor age, years (mean ± SD)	43.5 ± 10,9	43.6 ± 13.8	0.958
Donor gender, male, N (%)	60 (62.5)	47 (48.5)	0.050
Donor type, N (%)			0.005
Living	41 (42.7)	23 (23.7)	
Deceased	55 (57.3)	74 (76.3)	
Cause of donor death, N (%)			0.947
Cerebrovascular	34 (61.8)	49 (66.2)	
Head trauma	16 (29.1)	20 (27)	
Tumor	2 (3.6)	2 (2.7)	
Other	3 (5.5)	3 (4.1)	
Final donor creatinine, mg/dL (mean ± SD)	1.8 ± 1.3	1.7 ± 0.9	0.548
Cold ischemia time, hours (mean ± SD)	17.4 ± 6.3	14.8 ± 5.8	0.030

SD = Standard deviation

Table 2 - Incidence of CMV disease

Variable	r-ATG/EVR (N = 96)	BAS/MPS (N = 97)	P
Incidence of first CMV event, N (%)	4 (4.2)	17 (17.5)	0.005
Time to first CMV event, days (mean ± SD)	72.2 ± 43.1	82.1 ± 50.7	0.420
PCR, copies/mL (mean ± SD)	222.823,7 263.235,3	± 200.472,9 376.392,4	± 0.362
Duration of hospitalization treatment, days (mean ± SD)	11.7 ± 13.6	32.9 ± 8.8	0.005
Pretransplant CMV serostatus, N (%)	-	-	-
Donor (+)/Recipient (+)	2 (2.9)	6 (14.3)	0.051
Donor (+)/Recipient (-)	1 (100)	2 (50)	1.000
Donor (-)/Recipient (+)	0	0	-
Donor (-)/Recipient (-)	1 (100)	0	-
Donor (unk)/Recipient (-)	0	1 (50)	-
Donor (unk)/Recipient (+)	0	8 (24.2)	-
Recipient (+)	2 (2.1)	14 (15.6)	0.001
First CMV event after EVR discontinuation, N(%)	0	-	-

SD = Standard deviation

When we analyzed the recipients who were previously positive for CMV IgG, and we observed a statistically significant difference (2.1% x 15.6%, p=0,001), that was not observed in the negative CMV IgG recipients, probably due to the small sample. There was an important difference in the time of hospitalization to treat the CMV disease; patients of MPS stayed hospitalized for about 20 days longer than the EVR group (p=0.005), including 2 patients that did not need to be admitted for treatment.

DISCUSSION

Tedesco-Silva et al. assessed a group of de novo kidney transplant recipients treated with a single dose of antithymocyte globulin (ATG) and a reduced dose of tacrolimus and everolimus without CMV prophylaxis. A significant reduction in the incidence of CMV infection/disease was observed in comparison to the standard tacrolimus plus mycophenolate immunosuppressive regimen.^{20,33}

In a pooled analysis of over 2000 de novo RTX recipients in 2011, Brennan, et al. demonstrated that EVR was associated to a decrease and delay in the time to onset of CMV events compared to MPA.¹

CMV infection is associated to many deleterious indirect effects including rejection,^{1,11} IF/TA1,15 and mortality^{1,11-13} In addition to the potential for undesirable clinical outcomes associated to the CMV, there is also a negative economic aspect. Perhaps most costly, it is the economic burden of CMV-associated graft failure^{1,43}.

The use of an mTOR inhibitor as part of the immunosuppressive regimen could also be considered in recipients with CMV disease resistant to antiviral therapy. In a study of nine renal transplant recipients who had ganciclovir-resistant CMV42, a rapid decrease in antigenemia levels was observed after conversion to sirolimus and ganciclovir administration, and none of the recipients experienced acute rejection or CMV recurrence.¹⁷

Table 3 - Secondary endpoints

Variable	r-ATG/EVR (N= 96)	BAS/MPS (N= 97)	P
Treatment failure, N (%)	16 (16.7)	6 (6.2)	0.025
First biopsy confirmed acute rejection, N (%)	4 (4.2)	6 (6.2)	0.747
IA	0	1 (16.7)	-
IB	0	1 (16.7)	-
IIA	1 (25)	3 (50)	-
IIB	1 (25)	0	-
III	0	1 (16.7)	-
Mixed	1 (25)	0	-
Acute antibody-mediated rejection	1 (25)	0	-
Patient survival, 12 months, (%)	89.5	85.6	0.449
Graft survival, 12 months, (%)	88.5	80.4	0.102
Death-censored graft survival, 12 months (%)	98.9	94.5	0.079
DGF, N (%)	20 (36.4)	37 (50)	0.123
Duration of DGF, days (mean ± SD)	7.6 ± 6.2	10.7 ± 10.9	0.570
Creatinine, mg/dL (mean ± SD)			
3 months	1.9 ± 1.0	2.0 ± 0.9	0.175
6 months	1.8 ± 0.9	2.0 ± 0.8	0.111
12 months	1.9 ± 1.0	1.9 ± 1.2	0.67

SD - Standard deviation

The association of lower CMV with the use of EVR might be explained by relatively less potent immunosuppression. However, the acute rejection rates were similar between those who received EVR compared to MPA, suggesting that the “net state of immunosuppression” for any group was similar.^{1,2}

A higher number of patients in the EVR group needed discontinuation of the therapy ($p= 0,025$, Table 3), maybe because we use adjustment of dose for patients receiving MPS before discontinuation, and because of the lack of experience with the new drug at this point. These findings are consistent with the literature.^{44,45} There were no differences in DGF, graft or patient survival, acute rejection or creatinine levels.

Despite being a single-center retrospective study, the present analysis corroborates previous findings.^{20,33}

CONCLUSION

Results from this trial conducted in low immunological risk kidney transplants recipients receiving no CMV prophylaxis or preemptive therapy demonstrated that EVR was associated to a decrease in CMV disease incidence when compared to MPS. Except for the underrepresented high-risk population (D+/R-), these data suggest that kidney transplant recipients receiving EVR may not need CMV prophylaxis.

RESUMO

Introdução: Citomegalovírus (CMV) é a infecção viral mais comum após o transplante renal. CMV. Geralmente apresenta-se nos primeiros meses após o transplante. O uso de terapia profilática com antivirais resultou em queda da incidência, porém, CMV ainda permanece como uma comorbidade importante, associada com rejeição e perda do enxerto, mortalidade, fibrose intersticial e atrofia tubular (IF/TA) em biópsias protocolares e aumento de custo. **Objetivo:** Determinar a incidência de doença pelo citomegalovírus em receptores de transplante renal recebendo Everolimus e dose reduzida de Tacrolimus. **Materiais e Métodos:** Foi realizada análise retrospectiva envolvendo pacientes de baixo risco imunológico que receberam transplante renal na Santa Casa de Misericórdia de Juiz de Fora, entre Janeiro de 2013 e Fevereiro de 2017. O primeiro grupo recebeu indução com Basiliximab e terapia de manutenção pós-operatória com Tacrolimus, Ácido micofenólico e Prednisona (BAS/MPS) e o segundo grupo foi induzido com Globulina anti-linfócito (2,25mg/Kg) e regime de manutenção com Tacrolimus em baixa dose (2mg/10Kg/dia), Everolimus e Prednisona (r-ATG/EVR). Nenhum paciente realizou terapia preemptiva ou profilaxia contra CMV. **Resultados:** Pacientes que receberam EVR apresentaram menor incidência comparados aos que receberam MPS (4.2% x 17.5%, p=0.005). Houve importante diferença no tempo de hospitalização para tratamento de CMV; aqueles recebendo MPS permaneceram internados cerca de 20 dias mais do que o grupo EVR (p=0.005). Não foram observadas diferenças na incidência de rejeição, função retardada do enxerto ou sobrevida do enxerto. **Conclusão:** Resultados deste trabalho conduzido em receptores de transplante renal de baixo risco imunológico que não receberam profilaxia contra CMV demonstram que EVR está associado à menor incidência de doença por CMV, quando comparado à MPS. Esses dados sugerem que receptores de transplante renal recebendo EVR podem não usar profilaxia contra CMV.

Descritores: Citomegalovírus; Transplante renal; inibidores da mTOR.

REFERENCES

1. Brennan DC, Legendre C, Patel D, Mange K, Wiland A, McCague K, et al. Cytomegalovirus Incidence Between Everolimus Versus Mycophenolate in De Novo Renal Transplants: Pooled Analysis of Three Clinical Trials. *American Journal of Transplantation*. 2011;11: 2453–62.
2. Charfeddine K, Zaghden S, Kharrat M, Kamoun K, Jarraya F, Hachicha. J. Infectious complications in kidney transplant recipients: A single-center experience. *Transplant Proc*. 2005;37:2823–5.
3. George JA, Rama T, Scott AG, et al. Infectious complications after kidney transplantation: current epidemiology and associated risk factors. *Clin Transplant*. 2006;20:401–9.
4. Hwang EA, Kang MJ, Han SY, Park SB, Kim HC. Viral infection following kidney transplantation: Long-term follow-up in a single center. *Transplant Proc*. 2004;36:2118–9.
5. Andrassy J, Hoffmann VS, Rentsch M, Stangl M, Habicht A, Meiser B, et al. Is Cytomegalovirus Prophylaxis Dispensable in Patients Receiving an mTOR Inhibitor-Based Immunosuppression? A Systematic Review and Meta-Analysis. *Transplantation*. 2012;94:1208-17.
6. Fishman JA. Infection in solid-organ transplant recipients. *N Engl J Med*. 2007;357:2601.
7. Brennan DC, Garlock KA, Singer GG, et al. Prophylactic oral ganciclovir compared with deferred therapy for control of cytomegalovirus in renal transplant recipients. *Transplantation*. 1997;64:1843–6.
8. Lowance D, Neumayer HH, Legendre CM, et al. Valacyclovir for the prevention of cytomegalovirus disease after renal transplantation. *N Engl J Med*. 1999;340:1462–70.
9. Reischig T, Jindra P, Mares J, et al. Valacyclovir for cytomegalovirus prophylaxis reduces the risk of acute renal allograft rejection. *Transplantation*. 2005;79:317–24.
10. Paya C, Humar A, Dominguez E, et al. Efficacy and safety of valganciclovir versus oral ganciclovir for prevention of cytomegalovirus disease in solid organ transplant recipients. *Am J Transplant*. 2004;4:611–20.
11. Hartmann A, Sagedal S, Hjelmessaeth J. The natural course of cytomegalovirus infection and disease in renal transplant recipients. *Transplantation*. 2006;82(2 Suppl):S15–S17.

12. Sagedal S, Hartmann A, Nordal KP, et al. Impact of early cytomegalovirus infection and disease on long-term recipient and kidney graft survival. *Kidney Int.* 2004;66:329–37.
13. Sagedal S, Rollag H, Hartmann A. Cytomegalovirus infection in renal transplant recipients is associated with impaired survival irrespective of expected mortality risk. *Clin Transplant.* 2007;21:309–13.
14. Reischig T. Cytomegalovirus-associated renal allograft rejection: New challenges for antiviral preventive strategies. *Expert Rev Anti-infective Ther.* 2010;8:903–10.
15. Reischig T, Jindra P, Hes O, Bouda M, Kormunda S, Treska V. Effect of cytomegalovirus viremia on subclinical rejection or interstitial fibrosis and tubular atrophy in protocol biopsy at 3 months in renal allograft recipients managed by preemptive therapy or antiviral prophylaxis. *Transplantation.* 2009;87:436–44.
16. Ho M. Epidemiology of cytomegalovirus infections. *Rev Infect Dis* 1990; 12 Suppl 7: S701.
17. Nashan B, Gaston R, Emery V, Saemann MD, Mueller NJ, Couzi L, et al. Review of Cytomegalovirus Infection Findings With Mammalian Target of Rapamycin Inhibitor-Based Immunosuppressive Therapy in De Novo Renal Transplant Recipients. *Transplantation.* 2012;93:1075–85.
18. Kalil AC, Levitsky J, Lyden E, et al. Meta-analysis: The efficacy of strategies to prevent organ disease by cytomegalovirus in solid organ transplant recipients. *Ann Intern Med.* 2005;143:870.
19. Hodson EM, Jones CA, Webster AC, et al. Antiviral medications to prevent cytomegalovirus disease and early death in recipients of solid organ transplants: A systematic review of randomised controlled trials. *Lancet.* 2005;365:2105.
20. Tedesco-Silva H, Felipe C, Ferreira A, Cristelli M, Oliveira N, Sandes-Freitas T, et al. Reduced Incidence of Cytomegalovirus Infection in Kidney Transplant Recipients Receiving Everolimus and Reduced Tacrolimus Doses. *American Journal of Transplantation.* 2015;15:2655–64.
21. De Keyzer K, Van Laecke S, Peeters P, Vanholder R. Human cytomegalovirus and kidney transplantation: A clinician's update. *Am J Kidney Dis.* 2011;58:118–26.
22. Kotton CN. CMV: Prevention, diagnosis and therapy. *Am J Transplant.* 2013;13:24–40.
23. Beam E, Dioverti V, Razonable RR. Emerging cytomegalovirus management strategies after solid organ transplantation: Challenges and opportunities. *Curr Infect Dis Rep.* 2014;16:419.
24. Preiksaitis JK, Brennan DC, Fishman J, Allen U. Canadian society of transplantation consensus workshop on cytomegalovirus management in solid organ transplantation final report. *Am J Transplant.* 2005;5:218–27.
25. Reischig T, Jindra P, Hes O, Svecova M, Klaboch J, Treska V. Valacyclovir prophylaxis versus preemptive valganciclovir therapy to prevent cytomegalovirus disease after renal transplantation. *Am J Transplant.* 2008;8:69–77.
26. Roman A, Manito N, Maria Campistol J, et al. The impact of the prevention strategies on the indirect effects of CMV infection in solid organ transplant recipients. *Transplant Rev.* 2014;28:84–91.
27. Kotton CN, Kumar D, Caliendo AM, et al. International consensus guidelines on the management of cytomegalovirus in solid organ transplantation. *Transplantation.* 2010;89:779–95.
28. de la Torre-Cisneros J, Farinas MC, Caston JJ, et al. GESITRASEIMC/REIPI recommendations for the management of cytomegalovirus infection in solid-organ transplant patients. *Enferm Infecc Microbiol Clin.* 2011;29:735–58.
29. Santos CAQ, Brennan DC, Fraser VJ, Olsen MA. Delayed-onset cytomegalovirus disease coded during hospital readmission after kidney transplantation. *Transplantation* 2014;98:187–94.
30. Stern M, Hirsch H, Cusini A, et al. Cytomegalovirus serology and replication remain associated with solid organ graft rejection and graft loss in the era of prophylactic treatment. *Transplantation.* 2014;98:1013–18.
31. Sabé N, González-Costello J, Rama I, Niubó J, Bodro M, Roca J, et al. Successful outcome of ganciclovir-resistant cytomegalovirus infection in organ transplant recipients after conversion to mTOR inhibitors. *Transplant International* ISSN 0934-0874. *Transplant International* ^a 2012 European Society for Organ Transplantation. 25 (2012);e78–e82.
32. Eid Aj, Arthurs SK, Deziel PJ, Wilhelm MP, Razonable RR. Emergence of drug-resistant cytomegalovirus in the era of valganciclovir prophylaxis: therapeutic implications and outcomes. *Clin Transpl.* 2008;22:162.
33. Cervera C, Cofan F, Hernandez C, Soy D, Marcos MA, Sanclemente G, et al. Effect of mammalian target of rapamycin inhibitors on cytomegalovirus infection in kidney transplant recipients receiving polyclonal antilymphocyte globulins: a propensity score-matching analysis. *Transplant International.* 2016;29:1216–25.
34. Brennan DC, Aguado JM, Potena L, et al. Effect of maintenance immunosuppressive drugs on virus pathobiology: evidence and potential mechanisms. *Rev Med Virol.* 2013;23:97.
35. Lim WH, Eris J, Kanellis J, et al. A systematic review of conversion from calcineurin inhibitor to mammalian target of rapamycin inhibitors for maintenance immunosuppression in kidney transplant recipients. *Am J Transplant.* 2014;14:2106.
36. Fortun J, Martin-Davila P, Pascual J, et al. Immunosuppressive therapy and infection after kidney transplantation. *Transpl Infect Dis.* 2010;12:397.
37. Cervera C, Fernandez-Ruiz M, Villedor A, et al. Epidemiology and risk factors for late infection in solid organ transplant recipients. *Transpl Infect Dis.* 2010;13:598.
38. Ekberg H, Bernasconi C, Noldeke J, et al. Cyclosporine, tacrolimus and sirolimus retain their distinct toxicity profiles despite low doses in the Symphony study. *Nephrol Dial Transplant.* 2010;25:2004.

39. Webster AC, Lee VW, Chapman JR, Craig JC. Target of rapamycin inhibitors (sirolimus and everolimus) for primary immunosuppression of kidney transplant recipients: a systematic review and meta-analysis of randomized trials. *Transplantation*. 2006;81:1234.
40. de Paula MI, Medina Pestana JO, Nicolau Ferreira A, et al. Long-Term Follow-Up of De Novo Use of mTOR and Calcineurin Inhibitors After Kidney Transplantation. *Ther Drug Monit*. 2016;38:22–31.
41. Moorman NJ, Shenk T. Rapamycin-resistant mTORC1 kinase activity is required for herpesvirus replication. *J Virol*. 2010;84:5260–9.
42. Ozaki KS, Camara NOS, Nogueira E, et al. The use of sirolimus in ganciclovir-resistant cytomegalovirus infections in renal transplant recipients. *Clin Transplant*. 2007;21:675.
43. Schnitzler M. Costs and consequences of cytomegalovirus disease. *Am J Health Syst Pharm*. 2003;60(23 Suppl 8):S5–S8.
44. Zaza G, Granata S, Tomei P, Masola V, Gambaro G, Lupo A. mTOR inhibitors and renal allograft: Yin and Yang. *J Nephrol*. 22 April 2014.
45. Moes DJAR, Guchelaar HJ, Fijter JW. Sirolimus and everolimus in kidney transplantation. *Drug Discovery Today* Volume 00, Number 00 June 2015